2024 年度独立董事述职报告 各位股东及代表： 2024年，作为西藏奇正藏药股份有限公司（以下简称"公司"）独立董事， 本人始终坚守职责，依据《公司法》、《上市公司独立董事管理办法》、《上市 公司自律监管指引第1号——主板上市公司规范运作》等法规，以及《公司章程》、 《独立董事工作规则》，勤勉尽责，切实维护公司与全体股东尤其是中小股东的 合法权益。现将2024年度履职情况汇报如下： 一、基本情况 （一）个人履历 本人李春瑜，男，1973年1月生，中国国籍，无永久境外居留权。首都经济 贸易大学硕士、中国人民大学博士。现任公司独立董事，中国社会科学院工业经 济研究所副研究员。 （二）独立性自查情况 报告期内，本人任职符合《上市公司独立董事管理办法》、《深圳证券交易 所上市公司自律监管指引第1号——主板上市公司规范运作》中对独立董事独立 性的相关要求，不存在影响独立性的情况。 二、年度履职概况 （一）出席董事会、股东会情况 2024年度，公司召开董事会11次、股东会6次。本人亲自出席了任期内召开 的董事会和股东会，认真审议议案、审慎行使表决权，无缺席、委托他人出席或 连续两次未亲自出席的情形。 | 独立董 | 应 ...

2024年度独立董事述职报告 各位股东及代表： 2024年度，作为西藏奇正藏药股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《公司法》、《深圳证券交易所股票上市规则》、《上市公司 自律监管指引第1号——主板上市公司规范运作》等法律法规和《公司章程》、 《独立董事工作规则》等的规定，勤勉、忠实、尽责地履行职责，充分发挥独立 董事作用，维护公司整体利益和全体股东尤其是中小股东的合法权益。现将2024 年度履职情况报告如下： 一、基本情况 （一）个人履历 本人王玉荣，女，1976年10月生，中国国籍，无永久境外居留权。西安交通 大学计算机软件学士、上海交通大学企业管理硕士、西安交通大学管理科学与工 程博士。曾任上海汉普管理咨询有限公司副总经理。现任公司独立董事，上海企 源科技股份有限公司联合创始人/董事，浙江清源信息科技有限公司执行董事兼 经理，西利企源（上海）信息科技有限公司董事，陕西企程丝路产金科技发展有 限公司执行董事兼总经理，滨海云商金控（天津）投资集团有限公司监事，浙江 清华长三角研究院产业互联网研究中心主任，中国中小企业协会副会长、产业互 联网专委会主任，泸州老窖股份有限公司战略顾问、宁夏西 ...

2024 年度独立董事述职报告 各位股东及代表： 2024年度，作为西藏奇正藏药股份有限公司（以下简称"公司"）的独立董 事，本人严格按照《公司法》、《深圳证券交易所股票上市规则》、《上市公司 自律监管指引第1号——主板上市公司规范运作》等法律法规和《公司章程》、 《独立董事工作规则》等的规定，勤勉、忠实、独立地履行职责，充分发挥独立 董事作用，维护公司整体利益和全体股东尤其是中小股东的合法权益。现将2024 年度履职情况报告如下： 一、基本情况 （一）个人履历 本人果德安，男，1962年4月生，中国国籍，无永久境外居留权。北京医科 大学药学院生药学博士，美国德州理工大学化学系博士后。曾任北京大学药学院 教授，现任公司独立董事，中国科学院上海药物研究所研究员，中药标准化技术 国家工程研究中心主任，上海中药现代化研究中心主任，东阿阿胶股份有限公司 独立董事。 （二）独立性自查情况 报告期内，本人任职符合《上市公司独立董事管理办法》、《深圳证券交易 所上市公司自律监管指引第1号——主板上市公司规范运作》中对独立董事独立 性的相关要求，不存在影响独立性的情况。 二、年度履职概况 （一）出席董事会、股东会情况 202 ...

奇正藏药（002287）公告，2025年第一季度营收为4.03亿元，同比增长10.39%；净利润为7567.98万 元，同比下降22.35%。 ...

Company Milestones and Achievements - Tibet Cheezheng Tibetan Medicine Co., Ltd. has completed three significant milestones in its 30-year history, including being the first company to invest in poverty alleviation in Tibet and becoming a leader in the modernization of Tibetan medicine[5]. - The company has been recognized as a national-level high-tech enterprise and has won multiple awards, including the "2024 Golden Single Product" for over-the-counter drugs[41]. - The company has achieved significant brand recognition, being ranked 2nd in the bone injury category for OTC products in China and 28th in the top 100 Chinese traditional medicine companies[54]. - The core product, the pain relief patch, ranks first in the market share among external patches for musculoskeletal diseases in urban pharmacies[43]. - The company has established a comprehensive treatment model for musculoskeletal disorders, integrating various dosage forms such as patches and ointments[43]. Product Development and Innovation - The company has developed innovative products such as the pain relief patch, which combines traditional Tibetan medicine with advanced modern formulation techniques, enhancing product quality and patient experience[6]. - The company focuses on the development of traditional Tibetan medicine, with a product line that includes external pain relief and oral Tibetan medicines[44]. - The company is actively conducting evidence-based medical research to optimize product indications and enhance brand marketing[43]. - The company has successfully registered multiple products, including the Renqing Mangjue capsule and the Honghua Ruyi pill, which have received national recognition and patents[6]. - The company aims to modernize Tibetan medicine through research and development, focusing on unmet clinical needs and internationalization strategies[50]. Financial Performance - The company's operating revenue for 2024 reached ¥2,337,969,652.39, representing a 14.32% increase compared to ¥2,045,152,409.09 in 2023[26]. - The net profit attributable to shareholders for 2024 was ¥582,281,116.79, a slight increase of 0.19% from ¥581,198,850.19 in 2023[26]. - The net profit after deducting non-recurring gains and losses was ¥425,808,626.27, which is a 15.09% increase from ¥369,978,084.82 in 2023[26]. - The total assets at the end of 2024 were ¥6,790,420,367.07, reflecting a 7.81% increase from ¥6,298,478,593.58 at the end of 2023[26]. - The basic earnings per share for 2024 was ¥1.0981, a marginal increase of 0.08% from ¥1.0972 in 2023[26]. Market Expansion and Strategy - The company is focused on expanding its market reach beyond Tibet, leveraging its unique product offerings to meet diverse healthcare needs globally[9]. - The company has identified over 600 high-potential counties across more than 2,000 counties and cities nationwide, penetrating over 70% of high-potential markets[57]. - The company plans to enhance its marketing capabilities across various channels, including retail and e-commerce, while promoting its brand through academic and digital marketing strategies[131]. - The company is positioned to benefit from the increasing demand for healthcare due to the aging population and rising chronic disease rates[37]. - The company is leveraging modern technology to innovate and modernize traditional Tibetan medicine, aligning with national policies promoting the integration of digital health[37]. Social Responsibility and Cultural Heritage - The company has a strong commitment to social responsibility, being listed in the "Excellent Cases of Social Responsibility of Private Enterprises in China (2023)"[41]. - The company emphasizes the importance of cultural heritage and innovation in its operations, establishing connections with contemporary Tibetan medicine masters and organizing development conferences[7]. - The company is actively involved in cultural preservation and charitable initiatives, reflecting its commitment to social responsibility[174]. - The company launched the "Qixin Guardian" public welfare initiative, reaching 160 million people with the integrated solution for musculoskeletal pain[67]. Governance and Management - The company maintains a strong independent operational structure, ensuring no interference from controlling shareholders in decision-making[146]. - The board of directors consists of 7 members, with 4 external directors, including 3 independent directors, ensuring effective separation between management and operations[147]. - The company has established a comprehensive information disclosure management system to ensure timely and accurate communication with shareholders and regulatory bodies[151]. - The company has a performance assessment system for its directors and senior management, linking remuneration to company performance[178]. - The company has a dedicated human resources department that operates independently from the controlling shareholders, ensuring autonomous recruitment and management[154]. Research and Development - The company’s R&D team is engaged in evidence-based medicine research, collaborating with national key specialty research teams[61]. - Research and development expenses increased by 13.82% to ¥66,730,503.64, indicating a focus on innovation and product development[95]. - The company is currently conducting Phase III clinical trials for several new drug applications, aiming to enhance its product pipeline and market competitiveness[94]. - The company is focusing on enhancing its research and development quality and speed through collaboration with CROs and internal audits[140]. - The company plans to deepen the application of AI technology in training programs by 2025 to support high-quality development[192]. Marketing and Sales - The company has established a digital marketing management system to enhance decision-making efficiency through big data analysis[57]. - The sales team consists of over 1,700 members, utilizing a multi-channel marketing approach to expand market reach across various medical fields[52]. - The company has seen significant growth in online sales channels, particularly in B2C and O2O sales[65]. - The company emphasizes digital marketing transformation to capture the trend of online consumer behavior and enhance brand visibility[52]. - The company has achieved a significant increase in international sales, which rose by 290.86% to ¥3,171,745.33, compared to ¥811,470.98 in the previous year[83]. Investment and Financial Management - The total investment amount for the reporting period was CNY 2,506,703,904.11, representing a 67.96% increase compared to CNY 1,492,430,000.00 in the same period last year[106]. - The company issued 4,100,000 shares at a price of CNY 11.81 per share, raising a total of CNY 48,421,000, with a net amount of CNY 45,120,010 after deducting issuance costs[114]. - The company has not engaged in any securities or derivative investments during the reporting period[110][111]. - The company has established independent financial management systems and operates separate bank accounts, ensuring financial autonomy[158]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 17.976 million[178].

Financial Performance - The company's revenue for Q1 2025 was CNY 403,015,309.71, representing a 10.39% increase compared to CNY 365,098,756.48 in the same period last year[5]. - Net profit attributable to shareholders decreased by 22.35% to CNY 75,679,793.49 from CNY 97,460,837.34 year-on-year[5]. - The basic and diluted earnings per share fell by 22.47% to CNY 0.1425 from CNY 0.1838 in the same quarter last year[5]. - Net profit for the current period was ¥75,094,519.94, a decrease of 24.0% from ¥98,694,178.45 in the previous period[23]. - Total operating revenue for the current period reached ¥403,015,309.71, an increase of 10.4% compared to ¥365,098,756.48 in the previous period[22]. - Total operating costs amounted to ¥323,360,068.03, up from ¥299,888,820.46, reflecting a growth of 7.8%[22]. Cash Flow - The net cash flow from operating activities significantly improved to CNY 255,818,548.95, a 233.71% increase from a negative CNY 191,328,489.83 in the previous year[5]. - Cash flow from operating activities increased significantly to ¥779,219,257.76 from ¥218,276,103.92, marking a growth of approximately 257%[24]. - Cash inflow from investment activities rose to ¥649,590,484.38 from ¥310,023,126.95, an increase of about 109%[25]. - Net cash flow from investment activities improved to ¥101,593,821.93 from a negative ¥276,882,207.67[25]. - Cash inflow from financing activities was recorded at ¥552,027,349.50, up from ¥439,200,000.00[25]. - The net increase in cash and cash equivalents was ¥333,498,493.12, compared to a decrease of ¥32,301,704.19 in the previous period[25]. - The ending balance of cash and cash equivalents increased to ¥523,089,986.62 from ¥356,202,070.72[25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,714,750,640.52, down 1.11% from CNY 6,790,420,367.07 at the end of the previous year[5]. - The company’s total liabilities decreased by 1.08% to CNY 4,020,668,719.25 from CNY 4,064,375,038.17 at the end of the previous year[5]. - Total liabilities decreased to ¥2,645,695,845.76 from ¥2,677,107,646.35, a reduction of 1.2%[20]. - The total equity attributable to shareholders of the parent company was ¥4,020,668,719.25, down from ¥4,064,375,038.17, a decrease of 1.1%[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,704[13]. - Gansu Qizheng Industrial Group Co., Ltd. holds 68.64% of shares, totaling 364,546,473 shares, with 23,913,456 shares pledged[13]. - Tibet Yutuo Cultural Development Co., Ltd. holds 18.53% of shares, totaling 98,395,215 shares, with 3,000,000 shares pledged[13]. - The company plans to repurchase shares with a total amount not less than RMB 90 million and not exceeding RMB 160 million, at a maximum price of RMB 31.65 per share[15]. - As of March 31, 2025, the company has repurchased 148,800 shares, accounting for 0.0280% of the total share capital, with a total transaction amount of RMB 3,380,561[16]. Investment and Other Income - The company reported a significant increase in cash and cash equivalents, with a net increase of CNY 333,498,493.12, reflecting a 1132.45% improvement from a decrease of CNY 32,301,704.19 in the prior year[11]. - The fair value changes of financial assets resulted in a loss of CNY 18,669,206.06, a decrease of 33.61% compared to the previous year[9]. - The company’s investment income showed a significant decline, reporting a loss of CNY 3,334,451.19 compared to a profit of CNY 10,285,742.77 in the same period last year[9]. - Research and development expenses were ¥11,472,526.65, slightly down from ¥12,018,942.57, indicating a focus on cost management[22]. - Other comprehensive income after tax showed a negative net amount of ¥54,508.06, contrasting with a positive amount of ¥63,746.45 previously[23]. Operational Insights - The company did not report any new product launches or technological advancements during the conference call[26]. - The first quarter report was not audited, indicating a potential area for further scrutiny[26].

西藏奇正藏药股份有限公司 董事会对独立董事独立性自查情况的专项报告 西藏奇正藏药股份有限公司 董事会 二〇二五年四月二十五日 西藏奇正藏药股份有限公司（以下简称"公司"）根据《上市公司独立董事 管理办法》、《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》等要求，就公司在任独立董事果德安 先生、李春瑜先生、王玉荣女士的独立性情况进行评估并出具如下专项意见： 经核查独立董事果德安先生、李春瑜先生、王玉荣女士的任职经历以及签署 的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公 司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他 可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合 《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 1 号 ——主板上市公司规范运作》中对独立董事独立性的相关要求。 ...

ESG 2024 奇正藏药 环境、社会和公司治理报告 种 / 下 / 幸 / 福 获 / 取 / 自 / 在 微信扫码，即可订阅 "奇正藏药投资者关系平台"公众号 CONTENTS 目录 名誉董事长致辞 /01 董事长致辞 /02 总裁致辞 /03 文化传承 /38 5.1 藏医药文化的保护与传承 / 39 5.2 助力藏医教育事业发展 / 40 5.3 投身乡村振兴 开展公益活动 / 42 4.3 向善爱人的企业文化氛围 / 36 附录 /48 关键绩效 / 48 年度主要荣誉 / 50 合并财务报表中所包含的实体 / 52 香港联合交易所 ESG 指引 / 53 GRI 内容索引 / 56 "联合国全球契约十项基本原则"/ 59 关于本报告 /60 1995 年，是奇正藏药扎根西藏的元年。那一年，在雪山朝圣的途中，我凝望着藏区牛粪 炉的烟火，脑海中浮现出科学实验室的明光；眼前是雪域随风飘动的经幡，思绪又不禁飘向科 学仪器的精密构造。彼时，我在巨大的反差中顿悟：虽有差异与多元，但人类对提高生命质量 的追求是始终同频。 2024 年，我参加珠峰考察。在世界之巅，感受着藏医药哲学体系中"地、水、火、风、空" 五 ...

西藏奇正藏药股份有限公司 2024年度监事会工作报告 西藏奇正藏药股份有限公司（以下简称"公司"）监事会严格按照《公司章 程》的规定履行职责，公司监事会人员构成、召集、召开、通知、授权委托符合 法律、法规的要求。2024年，公司监事会根据《公司法》、《证券法》、《公司章程》 和《监事会议事规则》的有关规定，从切实维护公司利益和全体股东权益出发， 认真履行监督职责。报告期内公司监事会对公司重大的经济活动、董事及高级管 理人员履行职责的情况进行了有效监督和检查，对企业的规范运作和发展起到积 极作用。 一、报告期内监事会工作回顾 报告期内，监事会召开9次会议。 1、2024年4月10日，公司第五届监事会第二十次会议以通讯形式召开，会议 应到监事4人，实到4人。会议审议通过如下议案： （1）审议通过了《关于2019年限制性股票激励计划部分预留授予权益第四 个解除限售期解除限售条件成就的议案》； （2）审议通过了《关于提名公司第六届监事会非职工代表监事候选人的议 案》； （3）审议通过了《关于第六届监事会监事薪酬的议案》。 （1）审议通过了《2023年度监事会工作报告》； （2）审议通过了《2023年度财务决算报告》； ...

Industry Overview - Chinese herbal medicine is a unique drug used in traditional Chinese medicine for disease prevention and treatment, encompassing both herbal medicine and traditional Chinese drugs [1][5] - The market size of Chinese herbal medicine planting in China is projected to grow from 156.3 billion yuan in 2019 to 295.68 billion yuan in 2024, with a year-on-year growth rate of 30.2% [9] - The planting area for Chinese herbal medicine has increased from 52.5 million mu in 2019 to 59.56 million mu in 2024, reflecting a year-on-year growth rate of 5.87% [5][9] Industry Chain - The upstream of the industry chain includes the planting of Chinese herbal medicine, breeding of medicinal animals, and collection of raw materials, with key players such as Baiyunshan, Kangmei Pharmaceutical, and Yunnan Baiyao [2] - The midstream involves the processing and manufacturing of Chinese herbal products, including traditional Chinese medicine and herbal pieces, with companies like Kangmei Pharmaceutical and Huaren Sanjiu leading this segment [2] - The downstream focuses on the distribution and sales of Chinese herbal products through traditional pharmacies and e-commerce platforms [2] Market Dynamics - The demand for Chinese herbal medicine is increasing due to factors such as industrialization, urbanization, and an aging population, alongside supportive government policies [9] - The recognition of traditional Chinese medicine in international markets is also on the rise, contributing to the industry's rapid growth [9] Competitive Landscape - The competitive landscape of the Chinese herbal medicine planting industry is tiered based on registered capital, with the first tier exceeding 1 billion yuan, including companies like Yunnan Baiyao and Kunming Pharmaceutical [11][13] - The second tier has registered capital between 500 million to 1 billion yuan, featuring companies like Yibai Pharmaceutical and Dong'e Ejiao [11][13] - The third tier consists of companies with registered capital below 500 million yuan, such as Foci Pharmaceutical and Zhendong Pharmaceutical [11][13] Development Trends - The establishment of geographical indication and ecological planting models is accelerating the construction of authentic medicinal material protection zones [17] - The standardization of seeds and seedlings is expected to overcome industry bottlenecks, with significant improvements in the coverage of quality seeds [17] - International certifications such as EU organic certification and US NOP standards are becoming essential for export enterprises, enhancing the competitiveness of Chinese herbal products in global markets [18]